agomelatine + escitalopram

Agomelatine + escitalopram is a combination of two antidepressant drugs used in the management of major depressive disorder (MDD) and related psychiatric conditions. Agomelatine acts as an agonist at melatonin receptors 1 and 2 (MT1, MT2) and as an antagonist at the serotonin 5-HT2C receptor, helping to regulate circadian rhythms and improve mood. Escitalopram is a selective serotonin reuptake inhibitor (SSRI) that increases synaptic serotonin levels by inhibiting its reuptake via the sodium-dependent serotonin transporter. The combination has been studied for its potential to enhance antidepressant efficacy, improve sleep quality, reduce emotional blunting, and provide better improvement in attention function compared to monotherapy with either agent alone[1][2][3][5]. Clinical studies suggest that this combination may be particularly beneficial for patients with pronounced sleep complaints or those experiencing apathy or inadequate response to SSRI monotherapy.